SIRT1 in Secretory Organ Cancer
Mammalian silent information regulator 1 (SIRT1) is reported to play a role in cancers of the secretory organs, including thyroid, pancreatic endocrine, and ovarian tumors [1, 2, 3, 4]. A recent meta-analysis conducted on 37 selected studies of human cancers analyzed the correlations of overall surv...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2018-09-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fendo.2018.00569/full |
| _version_ | 1818864275922354176 |
|---|---|
| author | Raffaele Frazzi |
| author_facet | Raffaele Frazzi |
| author_sort | Raffaele Frazzi |
| collection | DOAJ |
| description | Mammalian silent information regulator 1 (SIRT1) is reported to play a role in cancers of the secretory organs, including thyroid, pancreatic endocrine, and ovarian tumors [1, 2, 3, 4]. A recent meta-analysis conducted on 37 selected studies of human cancers analyzed the correlations of overall survival (OS), disease-free survival (DFS) and relapse-free survival (RFS) with SIRT1 expression [5]. This study reported that SIRT1 overexpression was associated with a worse OS in liver and lung cancers, while it was not correlated with OS in breast cancer, colorectal cancer, or gastric carcinoma. Collectively, the meta-analysis revealed that an unfavorable OS was associated with SIRT1 expression for solid malignancies. Given the growing importance of this class of lysine/histone deacetylases in human endocrine malignancies, a rational and focused literature assessment is desirable in light of future clinical translations. |
| first_indexed | 2024-12-19T10:29:04Z |
| format | Article |
| id | doaj.art-2364328fe7564ddd99b008a673de5530 |
| institution | Directory Open Access Journal |
| issn | 1664-2392 |
| language | English |
| last_indexed | 2024-12-19T10:29:04Z |
| publishDate | 2018-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj.art-2364328fe7564ddd99b008a673de55302022-12-21T20:25:48ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922018-09-01910.3389/fendo.2018.00569395644SIRT1 in Secretory Organ CancerRaffaele FrazziMammalian silent information regulator 1 (SIRT1) is reported to play a role in cancers of the secretory organs, including thyroid, pancreatic endocrine, and ovarian tumors [1, 2, 3, 4]. A recent meta-analysis conducted on 37 selected studies of human cancers analyzed the correlations of overall survival (OS), disease-free survival (DFS) and relapse-free survival (RFS) with SIRT1 expression [5]. This study reported that SIRT1 overexpression was associated with a worse OS in liver and lung cancers, while it was not correlated with OS in breast cancer, colorectal cancer, or gastric carcinoma. Collectively, the meta-analysis revealed that an unfavorable OS was associated with SIRT1 expression for solid malignancies. Given the growing importance of this class of lysine/histone deacetylases in human endocrine malignancies, a rational and focused literature assessment is desirable in light of future clinical translations.https://www.frontiersin.org/article/10.3389/fendo.2018.00569/fullSIRT1cancersecretory organsacetylationepigenetic modulation |
| spellingShingle | Raffaele Frazzi SIRT1 in Secretory Organ Cancer Frontiers in Endocrinology SIRT1 cancer secretory organs acetylation epigenetic modulation |
| title | SIRT1 in Secretory Organ Cancer |
| title_full | SIRT1 in Secretory Organ Cancer |
| title_fullStr | SIRT1 in Secretory Organ Cancer |
| title_full_unstemmed | SIRT1 in Secretory Organ Cancer |
| title_short | SIRT1 in Secretory Organ Cancer |
| title_sort | sirt1 in secretory organ cancer |
| topic | SIRT1 cancer secretory organs acetylation epigenetic modulation |
| url | https://www.frontiersin.org/article/10.3389/fendo.2018.00569/full |
| work_keys_str_mv | AT raffaelefrazzi sirt1insecretoryorgancancer |